[1]朱鸿帆 陈挺松 谢应海① 吴申 姚文亿 从云 徐静 徐成臣① 王昊**.125I粒子条联合系统治疗对肝癌合并Ⅲ型门静脉癌栓的临床研究[J].中国微创外科杂志,2023,01(5):372-377.
　Zhu Hongfan*,Chen Tingsong*,Xie Yinghai,et al.Clinical Study of 125I Seed Strips Combined With Systemic Therapy in the Treatment of Hepatocellular Carcinoma Complicated With Type Ⅲ Portal Vein Tumor Thrombus[J].Chinese Journal of Minimally Invasive Surgery,2023,01(5):372-377.
点击复制

125I粒子条联合系统治疗对肝癌合并Ⅲ型门静脉癌栓的临床研究()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
01
期数:
2023年5期
页码:
372-377
栏目:
短篇论著
出版日期:
2023-05-25

文章信息/Info

Title:
Clinical Study of 125I Seed Strips Combined With Systemic Therapy in the Treatment of Hepatocellular Carcinoma Complicated With Type Ⅲ Portal Vein Tumor Thrombus
作者:
朱鸿帆 陈挺松 谢应海① 吴申 姚文亿 从云 徐静 徐成臣① 王昊**
(上海中医药大学附属第七人民医院肿瘤二科，上海200120)
Author(s):
Zhu Hongfan*;  Chen Tingsong*;  Xie Yinghai;  et al.
*Department of Oncology, Seventh People’s Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 200120, China
关键词:
肝细胞肝癌; Ⅲ型门静脉癌栓; 血管内近距离放射治疗
Keywords:
Hepatocellular carcinoma; Type Ⅲ portal vein tumor thrombosis; Endovascular brachytherapy
文献标志码:
A
摘要:
目的探讨125I粒子条联合系统治疗对于肝癌合并Ⅲ型门静脉癌栓(portal vein tumor thrombosis，PVTT)的有效性及安全性。方法回顾性分析2020年1月~2021年5月16例125I粒子条联合系统治疗的肝癌合并Ⅲ型PVTT资料。观察术后6~8周肿瘤应答有效率及不良反应，随访生存时间。结果针对癌栓，完全缓解(complete response，CR)1例，部分缓解(partial response，PR)15例，客观缓解率(objective response rate，ORR)100%(16/16)；针对肝癌，PR 3例，疾病稳定(stable disease，SD)8例，疾病进展(progressive disease，PD)5例，疾病控制率(disease control rate，DCR)69%(11/16)。16例中位总生存期(overall survival，OS)8.9月。术后均无严重不良反应，最常见不良反应为疼痛，对症治疗后好转。结论125I粒子条联合系统治疗对肝癌合并Ⅲ型PVTT的有效性及安全性满意。
Abstract:
ObjectiveTo investigate the effectiveness and safety of 125I seed strips combined with systemic therapy for hepatocellular carcinoma complicated with type Ⅲ portal vein tumor thrombosis (PVTT).MethodsA retrospective analysis was made on 16 patients with hepatocellular carcinoma complicated with type Ⅲ PVTT treated by 125I seed strips combined with systemic therapy from January 2020 to May 2021 in our hospital. The patients were followed up for survival time, and the disease response efficiency and the occurrence of adverse effects during 6-8 weeks after surgery.ResultsAssessed against tumor thrombus, there was 1 complete response (CR) and 15 partial response (PR), with an objective response rate (ORR) of 100% (16/16). Assessed against liver cancer, there were 3 cases of PR, 8 cases of stable disease (SD), and 5 cases of progressive disease (PD). The disease control rate (DCR) was 69% (11/16). The median overall survival (OS) of the 16 cases was 8.9 months. There were no serious adverse reactions after surgery, and the most common adverse reaction was pain, which was relieved after symptomatic treatment.Conclusion125I seed strips combined with systemic therapy shows high efficiency and good safety in the treatment of hepatocellular carcinoma complicated with type Ⅲ PVTT.

参考文献/References:

[1]Katagiri S,Yamamoto M.Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus.Surg Today,2014,44(2):219-226.
[2]Cheng SQ,Wu MC,Chen H,et al.Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein.Hepatogastroenterology,2007,54(74):499-502.
[3]Reig M,Forner A,Rimola J,et al.BCLC strategy for prognosis prediction and treatment recommendation:the 2022 update.J Hepatol,2022,76(3):681-693.
[4]Yoon SM,Ryoo BY,Lee SJ,et al.Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion:a randomized clinical trial.JAMA Oncol,2018,4(5):661-669.
[5]中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南(2022年版).中华消化外科杂志,2022,21(2):143-168.
[6]体能状态评分ECOG评分法.中华普通外科学文献(电子版),2012,6(6):556.
[7]Bruix J,Sherman M.Management of hepatocellular carcinoma.Hepatology,2005,42(5):1208-1236.
[8]姚雪松,李槐.不可手术切除的肝细胞癌的疗效评价标准——改良RECIST标准更可靠.介入放射学杂志,2012,21(3):177-179.
[9]Hong D,Zhou Y,Wan XT,et al.Brachytherapy with Iodine125 seeds for treatment of portal veinbranch tumor thrombus in patients with hepatocellular carcinoma.BMC Cancer,2021,21(1):1020.
[10]皋文君,刘砚燕,袁长蓉.国际肿瘤化疗药物不良反应评价系统——通用不良反应术语标准4.0版.肿瘤,2012,32(2):142-144.
[11]Kokudo T,Hasegawa K,Matsuyama Y,et al.Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion.J Hepatol,2016,65(5):938-943.
[12]刘开才,吕维富,周春泽,等.TACE治疗原发性肝细胞癌合并门静脉癌栓疗效及影响因素.中国介入影像与治疗学,2018,15(6):331-336.
[13]中国医师协会肝癌专业委员会.中国肝细胞癌合并门静脉癌栓诊疗指南(2021年版).中华医学杂志,2022,102(4):243-254.
[14]Wang W,Wang C,Shen J,et al.Integrated I125 seed implantation combined with transarterial chemoembolization for treatment of hepatocellular carcinoma with main portal vein tumor thrombus.Cardiovasc Intervent Radiol,2021,44(10):1570-1578.
[15]Yang M,Fang Z,Yan Z,et al.Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine125 seed strand for thetreatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone:a twoarm,randomised clinical trial.J Cancer Res ClinOncol,2014,140(2):211-219.
[16]Zhang ZH,Zhang W,Gu JY,et al.Treatment of hepatocellular carcinoma with tumor thrombus with the use of iodine125 seed strand implantation and transarterial chemoembolization:a propensityscore analysis.J Vasc Interv Radiol,2018,29(8):1085-1093.
[17]Li Y,Li H,Hu H,et al.Efficacy and safety of transcatheter arterial chemoembolization combined with either I 125 seed implantation or apatinib in hepatocellular carcinoma with portal vein tumor thrombosis:a retrospective comparative study.J Cancer Res Ther,2020,16(7):1691-1697.
[18]Jia Z,Jiang G,Tian F,et al.A systematic review on the safety and effectiveness of yttrium90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis.Saudi J Gastroenterol,2016,22(5):353-359.
[19]余天柱,罗剑钧,颜志平.血管内近程放疗与序贯三维适形放疗治疗门静脉主干癌栓的疗效对比.介入放射学杂志,2017,26(9):787-792.
[20]周永杰,马婧嶔,罗剑钧,等.血管内近程放疗联合经动脉化疗栓塞及索拉非尼治疗肝细胞肝癌合并门脉主干癌栓的疗效分析.中国临床医学,2019,26(1):46-52.

备注/Memo

备注/Memo:
基金项目：上海市卫生健康委员会基金(202040180，202040187)；上海中医药大学附属第七人民医院人才培养计划(XX2021-03) **通讯作者，Email：howard_123@163.com ①(安徽理工大学附属第一医院普外三科，淮南232007)
更新日期/Last Update: 2023-08-10